On September 29, 2026, Dianthus Therapeutics, Inc., a clinical-stage biotechnology company based in New York and Waltham, Massachusetts, revealed its plans for showcasing claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting in Orlando, Florida. The event, scheduled from September 29 to October 2, 2026, will feature one oral presentation and four poster presentations by Dianthus Therapeutics. As a company listed on Nasdaq under the symbol DNTH, Dianthus focuses on pioneering advanced treatments for severe autoimmune diseases. This development underscores their commitment to transforming disease management in this space and signifies a significant step forward in the realm of biotechnology research and innovation.
